Development, Commercialization and Supply Agreement - Additional Information (Detail)	1 Months Ended								3 Months Ended		6 Months Ended		12 Months Ended
	Jan. 31, 2022 USD ($)	Jan. 31, 2021 USD ($)	Feb. 29, 2020 USD ($)	Jan. 31, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2017 USD ($)	Mar. 31, 2016 USD ($)	Feb. 28, 2015 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Item	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2020 USD ($)
License And Collaboration Agreements [Line Items]
Revenue recognized related to upfront and milestone payments											$ 701,000	$ 662,000
Licenses revenue									$ 94,440,000	$ 154,488,000	189,070,000	296,658,000
Deferred revenue									16,008,000	17,970,000	16,008,000	17,970,000	$ 16,709,000		$ 18,632,000
Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									93,796,000	153,773,000	$ 187,782,000	295,156,000
Mochida Pharmaceutical Co., Ltd. | In-licenses
License And Collaboration Agreements [Line Items]
Milestones payment	$ 1,000,000.0	$ 1,000,000.0
Mochida Pharmaceutical Co., Ltd. | In-licenses | Research and Development Expense
License And Collaboration Agreements [Line Items]
Upfront payment														$ 2,700,000
Edding | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received								$ 15,000,000.0
Number of indications of the regulatory milestone events relating to the submission and approval | Item											3
Amounts to be received upon achievement of the regulatory milestone events									33,000,000.0		$ 33,000,000.0
Sales-based milestone event payment									120,000,000.0		120,000,000.0
Revenue recognized related to upfront and milestone payments											300,000	600,000
Deferred revenue									9,500,000		9,500,000		9,800,000
Edding | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue											7,400,000		7,100,000
Edding | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									0	100,000	0	100,000
Edding | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone									153,000,000.0		153,000,000.0
Amounts to be received upon achievement of the regulatory milestone events									15,000,000.0		15,000,000.0
Sales-based milestone event payment									50,000,000.0		50,000,000.0
Edding | Out-licenses | Minimum
License And Collaboration Agreements [Line Items]
Amounts to be received upon achievement of the regulatory milestone events									2,000,000.0		2,000,000.0
Sales-based milestone event payment									5,000,000.0		5,000,000.0
Edding | Out-licenses | Clinical Trial Application
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received							$ 1,000,000.0
Biologix FZCo | Out-licenses
License And Collaboration Agreements [Line Items]
Revenue recognition period of non-refundable up-front payment							10 years
Biologix FZCo | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									0	0	0	500,000
HLS | Out-licenses
License And Collaboration Agreements [Line Items]
Non-refundable up-front received						$ 5,000,000.0
Non-refundable milestone payment received			$ 2,500,000	$ 3,800,000	$ 2,500,000
Revenue recognized related to upfront and milestone payments											300,000	600,000
Deferred revenue									5,900,000		5,900,000		6,200,000
Non-refundable up-front received period						6 months
Non-refundable milestone payment received						$ 3,800,000
HLS | Out-licenses | Health Canada
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received						2,500,000
HLS | Out-licenses | Licensing Revenue
License And Collaboration Agreements [Line Items]
Licenses revenue											7,800,000		$ 7,500,000
HLS | Out-licenses | Product Revenue, Net
License And Collaboration Agreements [Line Items]
Licenses revenue									$ 2,300,000		$ 2,300,000
HLS | Out-licenses | Maximum
License And Collaboration Agreements [Line Items]
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone						50,000,000.0
HLS | Out-licenses | Achievement of REDUCE-IT Trial
License And Collaboration Agreements [Line Items]
Non-refundable milestone payment received						$ 2,500,000